$アークトゥルス セラピューティクス ホールディングス(ARCT.US$
アークチュラス社が、自己増幅型COVID-19 mRNAワクチン候補ARCT-154が第3相試験において主要効果エンドポイントを満たしたことを発表
https://finance.yahoo.com/news/arcturus-announces-self-amplifying-covid-113000171.html
アークチュラス社が、自己増幅型COVID-19 mRNAワクチン候補ARCT-154が第3相試験において主要効果エンドポイントを満たしたことを発表
https://finance.yahoo.com/news/arcturus-announces-self-amplifying-covid-113000171.html
翻訳済み
1
$ジョンソン エンド ジョンソン(JNJ.US$
Dengue compound backed by J&J shows potency against the virus and all known variants in mice
https://www.fiercebiotech.com/research/dengue-pill-backed-by-j-j-shows-potency-against-virus-and-all-known-variants-mice
Dengue compound backed by J&J shows potency against the virus and all known variants in mice
https://www.fiercebiotech.com/research/dengue-pill-backed-by-j-j-shows-potency-against-virus-and-all-known-variants-mice
$アークトゥルス セラピューティクス ホールディングス(ARCT.US$ARCT-154の臨床試験申請が承認され、次世代のSTARR™ mRNAワクチンがSARS-CoV-2デルタ株とその他の懸念される変異株を狙ったものに進んでいくことがアークトゥルス社によって発表されました。
https://finance.yahoo.com/news/arcturus-announces-approval-clinical-trial-130000038.html
https://finance.yahoo.com/news/arcturus-announces-approval-clinical-trial-130000038.html
翻訳済み
1
3
$ヴィル バイオテクノロジー(VIR.US$
Some preliminary positive results for sotrovimab
"The primary efficacy analysis of all 1,057 patients in the COMET-ICE trial demonstrated a 79% reduction (adjusted relative risk reduction) (p<0.001) in hospitalization for more than 24 hours or death due to any cause, by Day 29 compared to placebo, meeting the primary endpoint of the trial"
https://www.globenewswire.com/news-release/2021/06/21/2250117/0/en/GSK-and-Vir-Biotechnology-Announce-Continuing-Progress-of-the-COMET-Clinical-Development-Program-for-Sotrovimab.html
https://www.reuters.com/article/health-coronavirus-gsk-usa/study-confirms-gsk-vir-antibody-drug-reduces-hospitalization-death-in-covid-19-patients-idUSL3N2O32Q9...
Some preliminary positive results for sotrovimab
"The primary efficacy analysis of all 1,057 patients in the COMET-ICE trial demonstrated a 79% reduction (adjusted relative risk reduction) (p<0.001) in hospitalization for more than 24 hours or death due to any cause, by Day 29 compared to placebo, meeting the primary endpoint of the trial"
https://www.globenewswire.com/news-release/2021/06/21/2250117/0/en/GSK-and-Vir-Biotechnology-Announce-Continuing-Progress-of-the-COMET-Clinical-Development-Program-for-Sotrovimab.html
https://www.reuters.com/article/health-coronavirus-gsk-usa/study-confirms-gsk-vir-antibody-drug-reduces-hospitalization-death-in-covid-19-patients-idUSL3N2O32Q9...
2
$アークトゥルス セラピューティクス ホールディングス(ARCT.US$
02 June 2021
Primordial Genetics Grants Arcturus Therapeutics Exclusive License of an RNA Polymerase for Human and Animal Therapeutics
https://www.prnewswire.com/news-releases/primordial-genetics-grants-arcturus-therapeutics-exclusive-license-of-an-rna-polymerase-for-human-and-animal-therapeutics-301303621.html
02 June 2021
Primordial Genetics Grants Arcturus Therapeutics Exclusive License of an RNA Polymerase for Human and Animal Therapeutics
https://www.prnewswire.com/news-releases/primordial-genetics-grants-arcturus-therapeutics-exclusive-license-of-an-rna-polymerase-for-human-and-animal-therapeutics-301303621.html
$フートゥー・ホールディングス(FUTU.US$
The companies, FUTU AND TIGR, disclosed during earnings calls last month they are applying for licenses in Singapore and the U.S. that would allow local customers to trade digital currencies.
https://www.cnbc.com/2021/06/01/chinas-robinhood-rivals-pile-into-the-crypto-craze.html?recirc=taboolainternal
The companies, FUTU AND TIGR, disclosed during earnings calls last month they are applying for licenses in Singapore and the U.S. that would allow local customers to trade digital currencies.
https://www.cnbc.com/2021/06/01/chinas-robinhood-rivals-pile-into-the-crypto-craze.html?recirc=taboolainternal
$アップ・フィンテック・ホールディング(TIGR.US$
両社は、先月の決算発表で、地元の顧客がデジタル通貨を取引できるようにするライセンスをシンガポールと米国で申請していることを明らかにしました。
https://www.cnbc.com/2021/06/01/chinas-robinhood-rivals-pile-into-the-crypto-craze.html?recirc=taboolainternal
両社は、先月の決算発表で、地元の顧客がデジタル通貨を取引できるようにするライセンスをシンガポールと米国で申請していることを明らかにしました。
https://www.cnbc.com/2021/06/01/chinas-robinhood-rivals-pile-into-the-crypto-craze.html?recirc=taboolainternal
翻訳済み